Issue 3, 2011

Refinement and validation of an exposure model for the pharmaceutical industry

Abstract

Objectives: Assessment of worker's exposure is becoming increasingly critical in the pharmaceutical industry as drugs of higher potency are being manufactured. The batch nature of operations often makes it difficult to obtain sufficient numbers of exposure measurements and occupational exposure models may be useful tools in the exposure assessment process. This paper aims to describe further refinement and validation of an existing deterministic occupational exposure model to predict airborne exposure of workers in this industry. Methods: Workplace exposure assessment data (n = 381) containing all the contextual information required for the exposure model were collated from a multinational pharmaceutical company. The measured exposure levels ranged from 5 × 10−7 to 200 mg m−3 for largely task based samples, and included a range of handling activities, local control measures and abnormal operating conditions. Model input parameters for local control measures and handling activities were refined to reflect pharmaceutical situations. Results: The refined exposure model resulted in good correlations between the log-transformed model predictions and the actual measured data for the overall dataset (rs = 0.61, n = 381, p < 0.001) and at scenario level (rs = 0.69, n = 48, p < 0.001). The model overestimated scenarios with measured exposure levels <0.1 mg m−3 (rs = 0.69, bias = 0.71, n = 46, p < 0.001), and underestimated scenarios with higher measured concentrations (>0.1 mg m−3) (rs = 0.59, bias = −4.9, n = 33, p < 0.001). Including information on the refined sub-parameters improved the correlations, suggesting the uncertainty in the model parameters was partly responsible for the bias. Conclusion: Further scientific data from the pharmaceutical industry on model input parameters, particularly on the efficacy of local control measures, may help improve the accuracy of the model predictions. The refined exposure model appears to be a useful exposure assessment screening tool for the pharmaceutical industry.

Graphical abstract: Refinement and validation of an exposure model for the pharmaceutical industry

Article information

Article type
Paper
Submitted
29 Sep 2010
Accepted
16 Dec 2010
First published
24 Jan 2011

J. Environ. Monit., 2011,13, 641-648

Refinement and validation of an exposure model for the pharmaceutical industry

P. E. Mc Donnell, J. W. Cherrie, A. Sleeuwenhoek, A. Gilles and M. A. Coggins, J. Environ. Monit., 2011, 13, 641 DOI: 10.1039/C0EM00523A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements